Metodesnitazene

Metodesnitazene

Metodesnitazene is a synthetic opioid that is part of the benzimidazole class of opioids. It was first synthesized in the 1960s as part of a series of analgesic agents. Metodesnitazene is an analog of Etonitazene, which is approximately 1000-1500 times more potent than morphine in animal models.

History

Metodesnitazene was first synthesized in the 1960s by a team of chemists at the pharmaceutical company Janssen Pharmaceutica. The team was led by Paul Janssen, who was searching for a new, more potent analgesic agent. Metodesnitazene was one of several benzimidazole opioids synthesized during this time, including Etonitazene and Clonitazene.

Pharmacology

Like other opioids, Metodesnitazene acts on the mu-opioid receptor in the brain to produce its analgesic effects. It is believed to be a full agonist at this receptor, meaning it can fully activate the receptor to produce its effects. The exact potency of Metodesnitazene in humans is not known, but it is believed to be significantly more potent than morphine.

Legal Status

Metodesnitazene is a controlled substance in many countries, including the United States, where it is classified as a Schedule I drug under the Controlled Substances Act. This means it has a high potential for abuse and no accepted medical use.

See Also

• Opioid
• Benzimidazole
• Etonitazene
• Clonitazene
• Paul Janssen
• Janssen Pharmaceutica
• Mu-opioid receptor
• Schedule I drug
• Controlled Substances Act